HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
about
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsUpdate in lung cancer and mesothelioma 2012Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsSomatic DNA mutation analysis in targeted therapy of solid tumoursRole of HER2 in NSCLCA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesPredictive biomarkers in precision medicine and drug development against lung cancerCombating acquired resistance to tyrosine kinase inhibitors in lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesReview of the current targeted therapies for non-small-cell lung cancerAcquired resistance to EGFR-targeted therapies in colorectal cancerSignaling cross-talk in the resistance to HER family receptor targeted therapyMechanism for activation of mutated epidermal growth factor receptors in lung cancerAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-JunHeterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.A perspective on anti-EGFR therapies targeting triple-negative breast cancerMechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaMechanisms of resistance to EGFR-targeted drugs: lung cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesPolypharmacology in Precision Oncology: Current Applications and Future ProspectsEpidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Molecular pathways and therapeutic targets in lung cancerThe quest to overcome resistance to EGFR-targeted therapies in cancer.Molecular Testing of Lung CancersOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyEstablishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung CancerDrug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.
P2860
Q24339394-2EBB158F-94CA-4B6A-8020-146257F609B3Q24619675-05044AD5-A13A-4F83-8CBC-94BD407E7EE6Q26741814-11C1D745-15FD-4CA4-850B-8DB9D5F835A4Q26744339-437876C7-2FBD-40E7-A2B7-2BD25EE28996Q26770324-9C164698-5F5C-47A3-9409-DA4DAA5C9C71Q26781683-C6868B02-6F8C-4638-9FBD-51B9916FFC4CQ26797297-FB5D5596-D31E-47E5-AEB5-FEC265D6BEFAQ26824536-3AB73857-D7FC-4C67-BEAA-FD8A029324C6Q26824877-5800A0F5-EB70-45C7-8AB2-7E4302BEEBD9Q26828860-E36302DE-F541-463D-94C1-B4B70AECC270Q26865779-1F983096-6E22-4C58-A10A-3BF7941C08A0Q27014117-4F4709CA-221D-4536-9463-4323681482A3Q27015079-361E359F-F386-46C9-8512-281F47A7495EQ27022741-DA022830-BFFB-4152-BD96-87179D889214Q27027778-FD2B2299-E71B-464C-A8FB-DA11AA0B4CDEQ27679902-163B48A0-7E00-4F9E-B4AE-1D9A6738BA06Q27852116-D07B59BF-A858-4CF1-B60A-CD0D519D4429Q27852553-4B8BD1C3-5252-41F2-84E5-1F204E547479Q27853013-DFCA6D9B-983B-46A4-967D-2DF5D2E1B4E8Q27853015-9AB602AB-DEDF-421E-9FC0-6638E27B5259Q27853078-A3765B63-A82F-4D61-AAC1-15CFA650F2E5Q27853317-0FE4C7C9-3D2E-4111-8138-4CDD005A078BQ27853391-B5E3799A-6106-4D7D-A50D-DEE2260E7EBAQ28069867-6F0D24E7-FEFD-4132-9C76-A51A19352F35Q28069900-DD654FAD-10CE-4F23-B5C0-774B487427A5Q28077415-A08712FA-8142-4366-906C-1B46CE562052Q28079320-9C618C76-5FBC-49F7-96A5-6619C4DFA382Q28259999-00D29580-0E56-4589-9ADE-DBC11E034BA0Q28394310-22153625-95E4-4BC7-802E-D9CE4BBB3426Q30846907-9090BA8B-BB70-4A62-A409-1B00C79855BEQ30850656-17C16AEB-4D22-471A-8B93-B1DB24FEB523Q33572728-49497F26-03C8-418F-B5A8-4DCFDFE6CD2AQ33601653-C853C18D-B4B3-4E79-B613-55662F13BE3FQ33605906-D7F23589-82ED-4D9B-986E-ADC01560B8FDQ33688872-A75D0E18-E60E-449E-9D3F-10C19CCA6D7AQ33725976-3B9A4231-9FC6-40FF-A430-DA0B7611C2DCQ33729715-1318D934-F2D2-4622-BCF4-49B325DFD02BQ33757134-FE197C04-7ED8-4DBF-9DFD-9F53927413FCQ33776876-74E49716-D723-4A9A-978B-D944FD849381Q33938441-DEE9D348-9792-40BC-9C88-2F24FC5E40D4
P2860
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@ast
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@en
type
label
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@ast
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@en
prefLabel
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@ast
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@en
P2093
P2860
P50
P1433
P1476
HER2 amplification: a potentia ...... second-site EGFRT790M mutation
@en
P2093
Caroline A Nebhan
Greg J Riely
Kadoaki Ohashi
Ken Takezawa
Maria E Arcila
Mark G Kris
Paula J Spitzler
Vincent A Miller
Xiaoling Song
Yelena Y Janjigian
P2860
P304
P356
10.1158/2159-8290.CD-12-0108
P577
2012-09-05T00:00:00Z